खोज परिणाम - Weili Zhao

  • प्रदर्शित 1 - 3 परिणाम 3
परिणाम को परिष्कृत करें
  1. 1
    Factors associated with the export of traditional Chinese medicinal products: A stochastic frontier analysis.

    Factors associated with the export of traditional Chinese medicinal products: A stochastic frontier analysis. द्वारा Ying Chen, Shuduo Zhou, Zhongfei Pei, Weili Zhao, Jian Yang, Yunxuan Hu, Xiangning Feng, Ming Xu

    प्रकाशित 2025-01-01

    <h4>Background</h4>The export of traditional Chinese medicinal products is a pivotal force in enhancing the international recognition of Traditional Chinese Medicine (TCM). From 2013 to 2022, the export trend of traditional Chinese medicinal products demonstrated stable and rapid growth....

    पूर्ण विवरण

    पूर्ण पाठ प्राप्त करें
    लेख

    सूची में सहेजें
    में बचाया:
  2. 2
    Factors associated with the export of traditional Chinese medicinal products: A stochastic frontier analysis

    Factors associated with the export of traditional Chinese medicinal products: A stochastic frontier analysis द्वारा Ying Chen, Shuduo Zhou, Zhongfei Pei, Weili Zhao, Jian Yang, Yunxuan Hu, Xiangning Feng, Ming Xu

    प्रकाशित 2025-01-01 पूर्ण पाठ प्राप्त करें
    लेख

    सूची में सहेजें
    में बचाया:
  3. 3
    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma द्वारा Linyu Yang, Qiang Qiu, Jie Wang, Yi Wen, He Li, Rui Liang, Yunyu Feng, Fang Wang, Xiaojing Lin, Minghai Tang, Jianhong Yang, Heying Pei, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Ke Tan, Yongsheng Wang, Yiguo Hu, Lijuan Chen, Weili Zhao, Ting Niu

    प्रकाशित 2025-06-01

    Abstract Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly selective HDAC I/II binhibitor, exhibits excellent...

    पूर्ण विवरण

    पूर्ण पाठ प्राप्त करें
    लेख

    सूची में सहेजें
    में बचाया:

खोज साधन: